Summary
We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]. Patients had failed surgical biopsy ± resection and radiation therapy. All patients were treated initially with BCNU 150-300mg/m2 by intra-arterial or intravenous route every 6 weeks. After CT evidence of tumor progression, all patients received PCB 150mg/m2/day for 28 days every 8 weeks. Patient responses to BCNU were CR (0), PR (7), SD (12), progression (12), and to PCB CR (2), PR (9), SD (6), and progression (14). Kaplan-Meier estimates of median time to failure for all patients were shorter for BCNU, 5.0 months (range 1.5–20), than for PCB, 6.0 months (range 2–50+). There was a statistically significant difference (Mantel-Cox test, p=0.02) in the distribution of time to disease progression between the two drugs, especially for grade III tumors (p= 0.02). The cumulative proportion of patients without disease progression at 6 months was 26% while on BCNU, compared to 48% while on PCB; at 12 months the cumulative proportions were 3% for BCNU compared to 35% for PCB. Although there was no formal washout period between administration of the two drugs, no carryover effect was evident. These data provide further evidence that PCB has significant activity against malignant glioma and may, in fact, be more effective than BCNU.
Similar content being viewed by others
References
Walker M, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic glioma. J Neurosurg 49: 333–343, 1978
Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. NEJM 303:1323–1329, 1980
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batedorf U, Brooks WH, Hunt WE, Mealey J, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR, Wilson CB, Strike TA: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121–132, 1983
Shapiro WR, Green SB, Burger PC, Mehaley MS, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J, Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71: 1–9, 1989
Rodriguez LA, Prados M, Silver P, Levin VA: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64: 2420–2423, 1989
Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS: Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743–1746, 1990
Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1–17, 1988
Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mealey J, Ransohoff J, Mahaley MS: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772–781, 1992
Shiba DA, Weinkam RJ: Thein vivo cytotoxic activity of procarbazine and procarbazine metabolites against L1210 ascites leukemia cells in CDF1 mice and the effects of pretreatment with procarbazine, phenobarbital, diphenylhydantoin, and methylprednisolone uponin vivo procarbazine activity. Cancer Chemother Pharmacol 11: 124–129, 1983
Erikson JM, Tweedie DJ, Ducore JM, Prough RA: Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 49: 127–133, 1989
Brent TP, Houghton PJ, Houghton JA: O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitro-sourea. Proc Natl Acad Sci USA 82: 2987, 1985
Schold SC, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P: O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70: 573–577, 1989
Robins P, Harris AL, Goldsmith I, Lindahl T: Cross-linking of DNA induced by chloroethylnitrosourea is prevented by O6-methylguanine-DNA methyltransferase. Nucleic Acids Res 11: 7743–7758, 1983
Bodell WJ, Aida T, Berger MS, Rosenblum ML: Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1, 3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 7: 879–883, 1986
Shapiro WR, Shapiro JR: Principles of brain tumor chemotherapy. Seminars Onc 13: 56–69, 1986
Ali-Osman F: Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res 49: 5258–5261, 1989
Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiation Oncol Biol Phys 18: 321–324, 1990
Hellman RM, Calogero JA, Kaplan BM: Etoposide (VP-16), vincristine, and procarbazine in recurrent and primary gliomas. Proc ASCO 9: 93, 1990
Brem H, Mahaley S, Vick NA, Black KL, Schold SC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenealy JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441–446, 1991
Tomita T: Interstitial chemotherapy for brain tumors: review. J Neuro-Oncol 10: 57–74, 1991
Andreef M, Weite K: Hematopoietic colony-stimulating factors. Seminars Oncol 16: 211–229, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newton, H.B., Bromberg, J., Junck, L. et al. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neuro-Oncol 15, 257–263 (1993). https://doi.org/10.1007/BF01050072
Issue Date:
DOI: https://doi.org/10.1007/BF01050072